Epcoritamab Misses the U.S. Phase 3 Endpoint

Company Genmab / AbbVie Event Type Clinical Trial Results Clarification (Phase 3 Confirmatory Endpoint) Modality Bispecific T-Cell Engager (CD20×CD3 DuoBody) Asset Epkinly (epcoritamab-bysp) Target CD20 / CD3 Disease Area Relapsed or Refractory Diffuse Large B-Cell Lymphoma Summary Genmab and AbbVie clarified on July 23 that…